drugset / Trial / NCT01125514

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

NCT01125514

Phase 2 Completed 37 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupSingle-blindTreatment

Summary

This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.

Timeline

Start
2010-05
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg
Subject Furosemide Other / unclassified 60 mg

Indications